Cyclodextrin-Based Nanohydrogels Containing Polyamidoamine Units: A New Dexamethasone Delivery System for Inflammatory Diseases by Argenziano, Monica et al.
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional 
Repository 
 
 
 
 
 
This is the author's final version of the contribution published as: 
Monica Argenziano , Chiara Dianzani , Benedetta Ferrara , Shankar Swaminathan ,  
Amedea Manfredi , Elisabetta Ranucci , Roberta Cavalli and Paolo Ferruti  
Cyclodextrin-Based Nanohydrogels Containing Polyamidoamine Units: A New 
Dexamethasone Delivery System for Inflammatory Diseases 
Gels 3(2), 2017, 22-37 
DOI:10.3390/gels3020022 
 
 
The publisher's version is available at: 
http://www.mdpi.com/2310-2861/3/2/22 
 
When citing, please refer to the published version. 
 
 
Link to this full text:  
http://hdl.handle.net/ 2318/1661700 
           
 
Cyclodextrin-Based Nanohydrogels Containing 
Polyamidoamine Units: A New Dexamethasone Delivery 
System for Inflammatory Diseases 
Abstract: Glucocorticoids are widely prescribed in treatment of rheumatoid arthritis, asthma, systemic 
lupus erythematosus, lymphoid neoplasia, skin and eye inflammations. However, well-documented 
adverse effects offset their therapeutic advantages. In this work, novel nano-hydrogels for the sustained 
delivery of dexamethasone were designed to increase both bioavailability and duration of the administered 
drug and reducing the therapeutic dose. Hydrogels are soft materials consisting of water-swollen cross-
linked polymers to which the insertion of cyclodextrin (CD) moieties adds hydrophobic drug-complexing 
sites. Polyamidoamines (PAAs) are biocompatible and biodegradable polymers apt to create CD moieties in 
hydrogels. In this work, β or γ-CD/PAA nanogels have been developed. In vitro studies showed that a 
pretreatment for 24–48 h with dexamethasone-loaded, β-CD/PAA nanogel (nanodexa) inhibits adhesion of 
Jurkat cells to human umbilical vein endothelial cells (HUVEC) in conditions mimicking inflammation. 
This inhibitory effect was faster and higher than that displayed by free dexamethasone. Moreover, 
nanodexa inhibited COX-2 expression induced by PMA+A23187 in Jurkat cells after 24–48 h incubation in 
the 10−8–10−5 M concentration range, while dexamethasone was effective only at 10−5 M after 48 h treatment. 
Hence, the novel nanogel-dexamethasone formulation combines faster action with lower doses, suggesting 
the potential for being more manageable than the free drug, reducing its adverse side effects. 
Keywords: dexamethasone; cyclodextrin/polyamidoamine nanohydrogels; topical delivery; β- and γ-
Cyclodextrins; COX-2 expression 
 
1. Introduction 
Glucocorticoids (GCs) are anti-inflammatory and immunosuppressive agents widely used to treat 
systemic autoimmune diseases and a number of different conditions, such as asthma, skin diseases, eyes 
inflammations, allergic reactions, and cancers. They are also common medications in palliative care [1,2]. 
Despite their clinical efficacy, GCs cause several adverse reactions limiting their clinical usefulness. These 
adverse effects are mostly dependent on the duration and dosage of the therapy and are, therefore, 
particularly relevant in chronic diseases that require long-lasting treatments [3,4]. 
Dexamethasone is a potent glucocorticoid with a high effectiveness in downregulating the expression of 
anti-inflammatory cytokines. It is used to treat many ocular diseases and it is mainly administered as eye-
drops. Unfortunately, high drug concentrations can lead to severe local and systemic side-effects. Moreover, 
eye-drops are rapidly cleared and consequently frequent instillations of high doses of dexamethasone are 
required [5]. 
To enhance the efficacy of dexamethasone and control the release kinetics to the target site in the 
meantime, decreasing doses and minimizing toxicity, efficient biodegradable and biocompatible 
nanodelivery systems have been studied. Nanoparticles present a number of advantages for the ocular 
delivery of drugs, comprising controlled drug release, drug targeting, increased surface adhesion, and drug 
penetration through mucus membranes. Various nanocarriers with different characteristics and architectures 
have been studied for the topical delivery of dexamethasone. A number of liposomes have been proposed as 
dexamethasone delivery systems. The effects of formulation parameters on the liposome physico-chemical 
properties were deeply investigated, showing that dexamethasone incorporation and release from liposomes 
was dependent on the type of lipid used and their sizes [6,7]. Previously, β-cyclodextrin-based nanosponges 
were developed for dexamethasone ocular delivery. Nanosponge formulations showed prolonged drug 
release kinetics and an increase of dexamethasone corneal permeability compared to marketed formulations 
[8]. Moreover, “smart” polymer nanoparticles responsive to external stimuli, such as temperature and pH 
values, or with mucoadhesion properties, received much attention to improve the therapeutic effects and 
minimize side effects. Polymer nanoparticles able to swell with the pH values can be exploited for the design 
of nanoformulations with controlled and targeted release kinetics suitable for ocular administration.  
Very recently, dexamethasone-loaded Eudragit® RS (an anionic acrylate polymer) and ethyl cellulose 
nanoparticles exhibited the capability to adhere to the corneal surface and release the drug slowly and in a 
controlled manner over time [9]. Particularly, dexamethasone showed slower release kinetics in pH 4.5 acetic 
buffer than in pH 7.5 phosphate buffer. These results are in line with the swelling behavior of the acrylate 
polymer. 
In addition, pH-sensitive polymeric nanoparticles showed a great potential for dermal and 
transfollicular dexamethasone delivery [10]. 
In this context, recent advances in drug nanotechnology underline the role played by nanogels for the 
delivery of dexamethasone [11]. Nanogels are nanostructures consisting of hydrophilic polymer networks 
and are promising vehicles for the delivery of a variety of different therapeutic agents [12]. Swelling and 
shrinkage of nanogels can be induced by changes in pH or temperature providing a triggered drug release 
[13]. Nanogels of methylcellulose hydrophobized with N-tert-butylacrylamide and containing 
dexamethasone were formulated in order to improve the topical ocular therapy by reducing the dosage and 
frequency of administration. Interestingly, cyclodextrins (CDs) could be integrated as functional units of 
nanogels in polymer networks acting as carriers of molecules with poor water solubility. Moreover, CD-
based nanogels provide useful functionalities, such as effective bioconjugation, good adhesion to surfaces, 
controlled drug complexation, and drug release [14]. Moya-Ortega and colleagues showed that 
dexamethasone γ-cyclodextrin-based nanogel eye drops increased ocular bioavailability and gave high drug 
concentrations in the aqueous humor for at least 3 h after ocular administration in rabbits [15].  
Polyamidoamines (PAAs) are biocompatible and biodegradable synthetic polymers apt to create 
hydrogels, and previously exploited for nanomedicine formulations [16]. 
Combining PAAs and cyclodextrins, a new nanogel platform was designed aimed at improving the 
topical administration of dexamethasone. 
Here, we report on the development and in vitro characterization of a new ocular nanoformulation of 
dexamethasone, i.e., dexamethasone nanogel, attempting to ameliorate its therapeutic index by increasing 
the efficacy and decreasing the side effects.  
2. Results 
2.1. Characterization of Blank and Dexamethasone-Loaded Nanogels 
The synthetic procedure tuned for preparing cyclodextrin-based nanogels allowed to obtain either β- or 
γ-cyclodextrin moieties in the hydrogel network. Two hydrogels were prepared as previously described [17] 
with modifications and were named β-CD/PAA and γ-CD/PAA, respectively.  
The Fourier transformed infrared (FTIR) spectra of β-CD/PAA compared to β-CD are reported in Figure 
1. 
 
Figure 1. FTIR spectra of β-CD and β-CD/PAA. 
The presence of peaks around 1500 cm−1 detectable only in the spectrum of β-CD/PAA confirmed the 
interaction of β-CD with the cross-linked units. 
The two hydrogels were then reduced to nanometric size by the HPH technique, a top-down 
technology currently used as a pharmaceutical process for producing colloidal systems [18]. The procedure 
consisted of forcing a coarse hydrogel suspension in water with a piston having an applied pressure between 
100 and 1500 bar through a tiny gap (5–10 μm). The mechanical stresses caused fragmentation of hydrogel 
matrices, thus producing nanosized particles with the same swelling capability of the parent hydrogels. 
Interestingly, β-CD/PAA and γ-CD/PAA nanohydrogels were pH sensitive due to the amphoteric nature of 
their PAA portion. In particular, the swelling degree of both types of nanogels increased regularly from pH 
4.0 to 7.4. 
Figure 2 reports the swelling degree of the two nanogels as a function of the pH value of the external 
medium. It may be observed that β-CD/PAA nanogel always exhibited a higher water uptake capability than 
γ-CD/PAA. 
 
Figure 2. pH dependence of β-CD/PAA and γ-CD/PAA nanogel swelling in aqueous media. 
The β-CD/PAA nanogel showed a higher swelling degree compared to γ-CD/PAA nanogel; in 
particular at pH 7.4 an increase of 46% on the nanogel water uptake capability was observed. 
Both unloaded nanogels showed average sizes of about 300 nm with a narrow size distribution and 
negative surface charge. The incorporation of dexamethasone was easily achieved without organic solvents. 
β-CD/PAA and γ-CD/PAA nanogels were able to incorporate dexamethasone with a loading capacity of 
5.15% and 3.61%, respectively. 
The physico-chemical characteristics of dexamethasone-loaded β-CD/PAA and γ-CD/PAA nanogels are 
reported in Table 1. DLS analyses showed average diameters of about 310 nm and 370 nm for 
dexamethasone-loaded β-CD/PAA and γ-CD/PAA nanogels, respectively. The low polydispersity indices 
indicated a rather uniform population distribution due to the HPH step performed during the nanogel 
preparation. The zeta potential determination evidenced highly negative surface charges, with a ζ potential 
of about −30 mV, values essential for the physical stability of nanosuspensions, the electrostatic repulsions 
avoiding nanogel aggregation. Moreover, the negative charge can favor the interaction with mucin, which is 
positively charged. Indeed, a large amount of mucin was absorbed on the two nanogel surfaces, reaching a 
mucin binding efficiency of about 85%. 
Table 1. Sizes and ζ potential values of dexamethasone-loaded β-CD/PAA and γ-CD/PAA nanogels. 
Loaded Nanogels Average Diameter (nm) Polydispersity Index ζ-Potential (mV) 
β-CD/PAA 314 ± 3.5 0.10 −29.85 ± 1.5 
γ-CD/PAA 372 ± 5.1 0.11 −33.30 ± 1.8 
Transmission electron microscope image of blank and dexamethasone-loaded nanogels show the 
spherical shape of the system and confirmed the small sizes (Figure 3). 
 
Figure 3. TEM image of blank (A) and dexamethasone-loaded nanogels (B) (scale bar 150 nm). 
Figure 4 reports SEM images of the blank and dexamethasone-loaded nanogels. 
  
 
Figure 4. SEM image of blank (A) and dexamethasone-loaded nanogels (B) (scale bar 1 μm). 
Differential scanning calorimetry (DSC) analysis showed the incorporation of dexamethasone in the two 
types of nanogels. The absence of the drug endothermic peak (262–264 °C) in the thermograms of the loaded 
nanogels confirmed the occurrence of dexamethasone molecular interactions with the polymer matrices 
(Figure 5). 
 
Figure 5. DSC thermograms of dexamethasone (A) and dexamethasone-loaded β-CD/PAA (B) and γ-CD/PAA 
(C) nanogels. 
The in vitro release kinetics of dexamethasone from β-CD/PAA and γ-CD/PAA nanogels are reported in 
Figure 6. 
 
Figure 6. In vitro release kinetics of dexamethasone from β-CD/PAA (A) and γ-CD/PAA (B) nanogels at pH 
7.4. Results are shown as means ± SEM from three independent experiments (n = 3). 
Both nanogels showed a slow and prolonged release profile over time at pH 7.4 and no initial burst 
effect was observed. In particular, only 14% of dexamethasone was released from the β-CD/PAA nanogel 
after 6 h. On the contrary, after 6 h the percentage of dexamethasone recovered in the receiving phase from 
γ-CD-PAA was about 50%. 
Concerning nanogel safety, no significant hemolysis caused by β-CD/PAA and γ-CD/PAA nanogels, 
either blank or dexamethasone-loaded, was observed, confirming their good biocompatibility and the 
presence of tonicity values suitable for ocular administration. 
Based on their smaller size values, higher loading capability and on the slower release kinetics, β-
CD/PAA nanogel was selected for the cell experiments and was named as nanodexa. 
2.2. Effect of Dexamethasone or Nanodexa on Jurkat Cell Adhesion to IL-1β-Stimulated HUVEC 
GCs act on endothelial cells by decreasing vascular permeability, adhesion molecule expression, and 
production of IL-1 and prostaglandins (PGs). However, Kerachian et al. [19] also showed that high doses of 
GCs could sensitize HUVEC to the effect of inflammatory mediators favoring their development of pro-
adhesive features. Therefore, we performed our adhesion assays using HUVEC treated or not with the pro-
inflammatory cytokine IL-1β to mimic pro-inflammatory conditions. HUVEC were treated for 24–48 h with 
increasing concentration of either dexamethasone (dexa) or nanodexa (10−9–10−5 M), then stimulated or not 
with IL-1β for further 18 h and, finally, incubated with Jurkat cells in the adhesion assay for 45 min. Figure 7 
shows the effect of dexa or nanodexa on Jurkat cell adhesion to IL-1β-stimulated HUVEC after 24 h of 
treatment.  
  
(a) (b) 
Figure 7. Effect of HUVEC treatment with dexa and nanodexa on adhesiveness to Jurkat cells. HUVEC were 
pretreated or not with titrated amounts of dexa and nanodexa (10−9–10−5 M) for 24 h (a) and 48 h (b), 
stimulated with IL-1β for 18 h, then incubated with Jurkat cells for 45 min. Data are expressed as mean ± SEM 
(n = 5) of the percentage of inhibition versus the control.* p ≤ 0.05 and ** p ≤ 0.01 nanodexa versus dexa 
(significance was assessed with Student’s t-test for paired varieties). § p < 0.05; §§ p < 0.01, significantly different 
from untreated cells. 
Nanodexa inhibited Jurkat cell adhesion in a concentration-dependent manner; the effect was already 
significant at 10−7 M (about 40% inhibition), with maximal inhibition (about 60%) obtained at 10−6–10−5 M. By 
contrast, no significant inhibition was detected with any concentration of free dexa at this time. Extending 
the duration of the treatment to 48 h, adhesion inhibition was detectable also for dexa, but only in the 10−7–
10−5 M range of concentrations. By contrast, nanodexa was already effective at the 10−8 M dose and its 
concentration-response curve was substantially different from that of dexa (p ≤ 0.01).  
Figure 8 shows micrographs of the Jurkat adhesion assay on IL-1β-stimulated HUVEC untreated (a) or 
treated with 10−7 M of either dexa (b: 36% of inhibition) or nanodexa (c: 55% of inhibition) for 48 h. 
 
Figure 8. Fluorescent microscopy of Jurkat cells adherent to HUVECs that were not treated (a) or treated with 
dexa and nanodexa (b,c, respectively) (scale bar 10 μm; magnification 100×).  
2.3. Effect of Dexamethasone or Nanodexa on COX-2 Expression in Stimulated Jurkat Cells 
COX-2 is upregulated during pathological conditions, such as inflammation and cancer, and 
glucocorticoids inhibit induction of COX-2 expression in a variety of cell lines and in response to different 
stimuli [20,21]. Since COX-2 is upregulated in T cells upon activation, we compared the activity on this 
induction exerted by dexa and nanodexa in Jurkat cell activated by the phorbol ester PMA (15 ng/mL) and 
calcium ionophore A23187 (1 μM) [22] Jurkat cells were treated for 24–48 h with increasing concentration of 
dexa and nanodexa (10−8–10−5 M) and COX-2 expression was then stimulated with PMA+A23187. Figure 9 
shows the effect of dexa and nanodexa after 24 h (panel a, c) and 48 h (panel b, d) of treatment. While dexa 
inhibited COX-2 expression only by 35% at 10−7 M after 48 h incubation, nanodexa was already maximally 
active after 24 h in the 10−8–10−5 M concentration range. 
 
Figure 9. Effect of dexa or nanodexa on COX-2 expression in stimulated Jurkat. Jurkat were pretreated or not 
with titrated amounts of dexa or nanodexa (10−8–10−5 M) for 24 h (a,c, respectively) and 48 h (b,d, respectively) 
and then stimulated with PMA+A23187 for 18 h. Then, cells were lysed, and COX-2 expression was analyzed 
by Western blot. The bar graphs show data (mean ± SEM) normalized to β-actin, expressed as the percentage 
of inhibition versus the control. * p ≤ 0.05 (significance was assessed with one-way ANOVA and the Dunnett 
test). Top: Western blot analysis from a representative experiment. Bottom: Densitometric analysis of COX-2 
expression expressed in arbitrary units of three independent experiments. 
3. Discussion 
Two cyclodextrin-based nanogels were obtained with attractive and promising properties as new 
biomaterial for dexamethasone ocular delivery. A polymer architecture comprising cross-linked cyclodextrin 
units was purposely tuned to load lipophilic molecules in a hydrophilic matrix. Indeed, the two nanogels 
were able to incorporate dexamethasone in good amounts due to the interaction with the hydrophobic 
cyclodextrin cavities and polymer networks. It is worth noticing that dexametasone-CD complexes have 
been previously described in the literature [23–25]. Dexamethasone has a poor water solubility (about 0.1 
mg/mL) and CDs showed the capability to improve the solubility and the topical bioavailability of the drug 
[5]. Previous studies suggested that the A-ring of the steroid molecule was predominantly included in the 
cavity of CDs. The inclusion complexation of dexamethasone with a number of CDs were determined, 
showing that the stability constant values of β-CD and γ-CD complexes were 9560 and 37,300 M−1, 
respectively [26]. Here, the nanogel formulations were designed to increase the apparent water solubility of 
the drug and to enhance the contact time with the eye surface, key factors for improving the ocular drug 
delivery.  
The β-CD/PAA nanogel provided a more stable complexation of dexamethasone than γ-CD/PAA, as the 
drug loading capacity and the in vitro release kinetics demonstrated. This behavior appeared in contrast 
with the stability constant values of the dexamethasone with the two parent CDs, as previously reported 
[26]. Indeed, we speculated that the bonding of CDs with the cross-linking agents in the nanogels may 
distort the CD cavity, so modifying the complexation capability with a guest molecule, as previously 
observed with alkylcarbonates derivatives of γ-cyclodextrins [27].  
Intriguingly, the insertion of cyclodextrin moieties did not affect the high hydration properties of 
nanogels and the pH sensitive swelling capacity. Β-CD/PAA showed a greater water content in comparison 
to the one of γ-CD/PAA. Different cross-linking degree and dimensions of network nanochannels might be 
present in the polymer matrix of β-CD/PAA and γ-CD/PAA, due to the different sizes of the two 
cyclodextrins, i.e., 262 and 427 Å3 for β-CD and γ-CD, respectively. The differences in the polymer 
nanostructure might affect the water uptake capability of the two nanohydrogels.  
The in vitro release study showed prolonged release profiles of dexamethasone without a burst effect, 
but the drug kinetics varied according to the type of nanogels. The observed differences might be related to 
the presence of different nanochannel network in the polymer matrices, besides different interactions with 
the CD cavities. The slow and constant dexamethasone release might be useful to achieve a sustained drug 
concentration in the tear fluid on the eye surface. 
For effective topical drug delivery into the eye, various polymer nanodelivery systems have been 
described in the literature showing a great potential to control the release kinetics and the penetration of 
corticosteroid [9,23].  
Considering a possible future clinical application of the new dexamethasone delivery system the 
pharmacology activity was evaluated. 
Dexamethasone is widely used for its ocular anti-inflammatory effect [1,28–30] but can also treat 
lymphoid neoplasia [31], and it has been used in solid cancer therapies in combination with antitumor 
drugs, such as 5-fluorouracil and cisplatin [32]. It exerts its anti-inflammatory and immunosuppressive 
effects by reducing the expression of cytokines and adhesion molecules, inhibiting leukocyte trafficking and 
access to inflammation sites and interfering with leukocyte, fibroblast and endothelial cell function. In this 
work, to evaluate the nanodexa activity, Jurkat cells were used to assess the inhibitory effect on adhesion to 
human umbilical vein endothelial cells (HUVEC) and COX-2 expression. Interestingly, we found that 
nanodexa inhibited Jurkat cell adhesion to HUVEC and COX-2 expression with earlier effects and at lower 
doses than free dexamethasone.  
The anti-inflammatory and immunosuppressive actions of GCs are exerted by two different 
mechanisms. In the classic genomic pathway, dexamethasone modulates the expression of proteins via their 
interactions with the cytosolic GC receptor (GR). However, GCs can also act by non-genomic mechanisms 
[33]. The genomic pathway is considered responsible for many adverse effects of GCs, most of which are 
time- and dose-dependent, such as osteoporosis, osteonecrosis, cataracts, hyperglycemia, coronary heart 
disease, and cognitive impairment, among others [34]. Consequently, the dose decrease is a key factor to 
control side effects of dexamethasone.  
The marked anti-inflammatory effect obtained with nanodexa at lower concentration of the drug may 
play an important role in decreasing the administered dose and the adverse side effects. 
Inflammation involves adhesive interactions between circulating leukocytes and endothelial cells lining 
the vascular wall. In response to various stimuli, such as the pro-inflammatory cytokines TNF-alfa, IL-1 beta, 
INF-gamma, and endothelial cells undergo inflammatory activation, producing an increased surface 
expression of cell adhesion molecules (CAMs), such as ICAM-1, VCAM-1, and E-selectin [35]. These 
endothelial CAMs play a fundamental role in leukocyte recruitment from the blood for tissue infiltration. 
Chronic induction of these CAMs leads to abnormal leukocyte recruitment, as seen in chronic inflammatory 
diseases [36]. Therefore, the effective inhibitory activity displayed by nanodexa on CAM expression by 
“inflamed” endothelial cells may be beneficial in blunting detrimental inflammatory reactions [37,38]. 
Even the potent inhibitory effect of nanodexa on COX-2 expression is intriguing. Prostaglandins (PGs) 
are known to be an important mediators of acute inflammation. They are synthesized by cyclooxygenase, 
comprising the constitutively expressed isoform COX-1 and the inducible isoform COX-2. COX-1 is 
expressed in most tissues that generate PGs during their normal physiological functions, and its expression 
does not fluctuate in response to stimuli. In contrast, COX-2 induction has critical roles in the response to 
tissue injury and infection and is an essential component of the inflammatory response and tissue repair [39]. 
Although the physiological activity of COX-2 may provide a definite benefit to the organism, its aberrant or 
excessive expression has been implicated in the pathogenesis of many diseases, such as chronic 
inflammations [40]. Taking into account that the positive effects of dexamethasone-loaded nanogels are 
exerted through earlier effectiveness and at lower doses than those of free dexamethasone, it may be 
hypothesized that this innovative nanogel formulation may increase the therapeutic efficacy with less 
adverse reactions. Finally, the small sizes and the mucoadhesive property of nanodexa can favor the ocular 
retention of the nanoformulation, contributing to the sustained release of the drug at the target site [41]. This 
might provide a long-lasting pharmacological activity with less frequent dexamethasone instillations. 
4. Conclusions 
Two promising cyclodextrin-based pH-sensitive nanogels were obtained. Morphological and physico-
chemical properties of the dexamethasone-loaded nanogels made them suitable as prolonged release 
delivery systems for ocular administration. 
Taken together, the in vitro results demonstrated that the β-CD/PAA dexamethasone nanoformulation 
is effective at lower doses and with faster onset compared to the free drug. 
Therefore, dexamethasone in CD-PAA nanogels may represent a potential novel strategy to formulate 
eye drops able to overcome the shortcomings of this drug. 
5. Materials and Methods 
5.1. Materials 
All materials were from Sigma-Aldrich (St. Louis, MO, USA). All reagents were of analytical grade. 
5.2. PAA Hydrogel Synthesis 
Two hydrogels were prepared as previously described [16] with modifications. Briefly, the polyaddition 
reaction between prim-or bis-sec-amines and bisacrylamides leads to polyamidoamines (PAAs). At pH ≥ 11.5 
the hydroxyl groups of cyclodextrins react with bisacrylamides in the same way and cyclodextrins behave as 
multifunctional monomers and give cross-linked polymer named nanosponges. With bisacrylamides, 
mixtures of cyclodextrins and amines give copolymeric hydrogels. The CD-containing hydrogels used in this 
work were prepared from 2,2-bisacrylamido acetic acid (BAC) as bisacrylamide, 2-methyl piperazine (2-MP) 
as amine and β- or γ cyclodextrin. The resultant hydrogels were named β-CD/PAA and γ-CD/PAA, 
respectively. In them, the PAA short chains connecting the CD moieties contained carboxyl- and amine 
groups and, in principle, had amphoteric properties. In a typical procedure, β-CD/PAA was prepared 
dissolving β-CD (734.84 mg, 0.62 mmol) and LiOH·H2O (77.7 g, 1.83 mmol) in H2O (0.4 mL) in a test tube. 
BAC (188.7 mg, 0.935 mmol) and LiOH·H2O (39.6 mg, 0.935 mmol) were dissolved in H2O (0.3 mL) in a 
second test tube, then 2-methylpiperazine (93.7 mg, 0.935 mmol) was added. The two solutions were 
thoroughly mixed and allowed to react at 25 °C for 48 h. The final product appeared as a homogeneous, 
transparent, and soft gel, which was tritured under water, and purified by repeated water/ethanol extraction 
cycles. The nanosponge sample was first soaked in deionized H2O (50 mL) and allowed swelling for 2 h, the 
pH was lowered to 5 with HCl 37% w/w then the nanosponge was soaked in ethanol (50 mL) for 2 h. This 
procedure was repeated three times. The product was dried to a constant weight. Yield: 76%. 
γ-CD/PAA was prepared following the same procedure described for β-CD/PAA. The monomers used 
and their amounts are reported below. The γ-CD was dissolved at about 95 °C.  
γ-CD/PAA: γ-CD (1030.52 mg, 0.77 mmol), LiOH·H2O (158.4 mg, 3.74 mmol), H2O (0.7 mL), BAC (192.4 
mg, 0.96 mmol), LiOH·H2O (40.8 mg, 0.96 mmol), H2O (0.3 mL), 2-methylpiperazine (96.3 mg, 0.96 mmol). 
Yield: 45%. 
5.3. FTIR Analysis 
Fourier transformed infrared (FTIR) spectra of β-CD and β-CD/PAA were obtained using a Perkin 
Elmer Spectrum 100 FT-IR in the region of 4000–650 cm−1. Data acquisition was done by Spectrum software 
version 10.03.05 (Perkin Elmer Corporation, Waltham, MA, USA). 
5.4. Swelling Capacity Evaluation 
The swelling capacity of nanogels was evaluated by gravimetric analysis. A weighted amount of dry β-
CD/PAA or γ-CD/PAA (Wd) was dispersed in 5.0 mL of PBS buffer at different pH values (i.e., 1, 4, 5, 6, 7.4). 
The mixture was stirred at 25 and 37 °C overnight. The supernatant was removed and then the wet weight 
(Ww) of the nanogels was measured. The swelling capacity (Sc) was calculated as the following equation: Sc = 
(Ww − Wd)/Wd. 
5.5. Nanogel Preparation by HPH 
Nanogels were obtained using a top down method. To this purpose, β-CD/PAA or γ-CD/PAA were 
suspended in saline solution (NaCl 0.9% w/v) at a concentration of 10 mg/mL and homogenized using a high 
shear homogenizer (Ultraturrax) for 10 min at 24,000 rpm. To further reduce the size of the nanogels and 
obtain an almost homogenous nanoparticle distribution, the sample underwent to high pressure 
homogenization for 90 min at a back-pressure of 500 bar, using an EmulsiFlex C5 instrument (Avastin, 
Ottawa, ON, Canada). The nanogels were then purified by dialysis (membrane cutoff of 12,000 Da) to 
eliminate potential synthesis residues. 
5.6. Preparation of Dexamethasone-Loaded Nanogel 
Dexamethasone was incorporated in the pre-formed nanogels, by the addition of dexamethasone (1 
mg/mL) to the aqueous nanosuspension of β-CD/PAA or γ-CD/PAA. Then, the mixture was stirred at room 
temperature in dark conditions over night. A purification step by dialysis (Spectrapore, Rancho Dominguez, 
CA, USA, cellulose membrane, cutoff of 12,000 Da) was carried out to eliminate the unbounded drug. 
5.7. Physico-Chemical Characterization of Nanogels 
The average diameters and polydispersity indices of nanogels were determined, after their dispersion in 
water, by photon correlation spectroscopy (PCS) using a 90 Plus Instrument (Brookhaven, NY, USA) at a 
fixed angle of 90° and at a temperature of 25 °C. Each sample was analyzed in triplicate. The nanogel zeta 
potentials were measured by electrophoretic mobility (90 Plus Instrument, Brookhaven, NY, USA). For zeta 
potential determination, the samples were diluted in water and placed in the electrophoretic cell, where an 
electric field of approximately 15 V/cm was applied. The morphology of nanogels was evaluated by 
scanning electron microscopy and transmission electron microscopy. For TEM analysis a Philips CM 10 
transmission electron microscope was used. The samples were sprayed on Formwar-coated copper and air-
dried before observation. 
5.8. Thermal Analysis 
Differential scanning calorimetry (DSC) was carried out by means of a Perkin Elmer DSC/7 differential 
scanning calorimeter (Perkin-Elmer, Waltham, MA, USA) equipped with a TAC 7/DX instrument controller. 
The instrument was calibrated with indium for melting point and heat of fusion. A heating rate of 10 °C/min 
was employed in the 25–250 °C temperature range. Standard aluminum sample pans (Perkin-Elmer) were 
used; an empty pan was used as a reference standard. Analyses were performed in triplicate on 3 mg freeze-
dried samples under a nitrogen purge. 
5.9. In Vitro Release Kinetics of Dexamethasone from Nanogels 
In vitro drug release experiments were conducted in a multi-compartment rotating cell, comprising a 
donor chamber separated by a cellulose membrane (Spectrapore, cut-off = 12,000 Da) from a receiving 
chamber. One milliliter of dexamethasone-loaded nanogels was placed in the donor chamber. The receiving 
compartment contained 1 mL of phosphate-buffered saline (PBS) at pH 7.4 with 0.1% sodium dodecyl sulfate 
(SDS) to assure drug solubility. The receiving phase was withdrawn at regular intervals and completely 
replaced with the same amount of fresh solution, to maintain sink conditions. The concentration of 
dexamethasone in the withdrawn samples was detected by HPLC.  
For the dexamethasone quantitative determination an HPLC analysis was performed using a Perkin 
Elmer pump (Perkin Elmer PUMP 250B, Waltham, MA, USA) equipped with a spectrophotometer detector 
(Flexar UV/Vis LC spectrophotometer detector, Perkin Elmer, Waltham, MA, USA). A reversed phase 
Agilent TC C18 column (150 cm × 4.6 mm, pore size 5 μm; Agilent Technologies, Santa Clara, CA, USA) was 
used. A mixture of acetonitrile −25 mM phosphate buffer pH 3 (27:73, v/v) was used as the mobile phase at a 
flow rate of 1.0 mL/min and the effluent monitored by measuring absorbance at 246 nm. HPLC 
chromatograms of dexamethasone are reported in Supplementary Material (Figure s1). 
5.10. Mucoadhesion Test 
The in vitro evaluation of the mucoadhesive properties of nanogels was carried out. To this purpose, 
the interaction between mucin and nanogels was determined by turbidimetric assay.  
Stock solutions of mucin (from porcine stomach) were prepared in water in the concentration range 
from 0.1 to 1 mg/mL. The transmittance of mucin solutions was measured at 500 nm with an UV 
spectrophotometer and a calibration curve was obtained. 1 mL of β-CD/PAA suspension was mixed with 
mucin stock solution and incubated under magnetic stirring for 30 min. Then, the samples were centrifuged 
for 5 min at 10,000 rpm and the transmittance of the supernatant, which contains the mucin non-adhesive to 
the β-CD/PAA hydrogel, was measured at 500 nm. 
5.11. Determination of the Hemolytic Activity 
For hemolytic activity determination, 100 μL of nanogels were incubated at 37 °C for 90 min with 
diluted blood (1:4 v/v) obtained by adding freshly-prepared PBS at pH = 7.4. After incubation, nanogels-
containing blood was centrifuged at 1000 rpm for 5 min to separate plasma. The amount of hemoglobin 
released due to hemolysis was determined spectrophotometrically (absorbance readout at 543 nm using a 
Duo spectrophotometer, Beckman, Brea, CA). The hemolytic activity was calculated to reference with 
nanogel-free diluted blood. Complete hemolysis was induced by the addition of ammonium sulfate (20% 
w/v). 
Optical microscopy was used to evaluate changes in red blood cell morphology after incubation with 
the formulations. 
5.12. Cell Culture 
HUVEC were isolated from human umbilical veins by trypsin treatment (1%) and cultured at 37 °C (5% 
CO2, 85–95% humidity) in M199 medium with the addition of 20% fetal calf serum (FCS) and 100 U/mL 
penicillin, 100 μg/mL streptomycin, 5 UI/mL heparin, 12 μg/mL bovine brain extract, and 200 mM 
glutamine. HUVEC were grown to confluence in flasks and used at the 2nd–5th passage. Informed consent 
was obtained from all donors. All subjects gave their informed consent for inclusion before they participated 
in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was 
approved by the Ethics Committee of Turin University (Project DIAC_RLO1601). HUVEC viability was not 
affected by the treatment with the drug.  
Leukemic human T cells (Jurkat, clone E6-1) were obtained from the American Type Culture Collection 
(ATCC; Manassas, VA, USA), and were cultured in RPMI 1640 medium supplemented with 10% FCS, 100 
U/mL penicillin, and 100 μg/mL streptomycin at 37 °C in a 5% CO2 humidified atmosphere.  
5.13. Cells Adhesion Assay 
HUVEC were grown to confluence in 24-well plates, washed, and rested for one day in M199 plus 10% 
FCS. The cells were incubated or otherwise with increasing concentrations of dexa or nanodexa (10−9–10−5 M) 
for 24–48 h, washed with fresh medium twice, stimulated for 24 h with IL-1β 1 ng/mL, and incubated with 
the Jurkat cells (1 × 105 cell/well) for 45 min; this incubation time was chosen to allow full sedimentation of 
the adhering cells. After incubation, non-adherent cells were removed by being washed three times with 
M199. The centre of each well was analysed by fluorescence image analysis [33]. Adherent cells were 
counted by the Image Pro Plus Software for micro-imaging (Media Cybernetics, Rockville, MD, USA, version 
5.0). Single experimental points were assayed in triplicate, and the standard error of the three replicates was 
always below 10%. Percentage inhibition of adhesion was calculated as follows: (100 − (a)/(b)) × 100, where a 
is adhesion measured in the presence of the compound plus stimulus minus basal adhesion and b is 
adhesion elicited by stimulus minus basal adhesion. The adhesion measured on untreated cells was 25 ± 2 
cells/microscope fields, and on IL-1β-stimulated cells was 58 ± 6 cells/microscope fields (n = 19).  
5.14. Protein Extraction and Western Blot Analysis  
In order to compare dexa with nanodexa effects on COX-2 expression, Jurkat cells were pre-treated with 
increasing concentrations of the drugs (10−8–10−5 M) for 24–48 h, and then stimulated with Phorbol 12-
myristate 13-acetate (PMA) 15 ng/mL + A23187 1 μM for 18 h. 
Cells were lysed in a buffer composed of 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% 
NP40, phosphatase, and protease inhibitor cocktails. Cell lysates were cleared from insoluble fractions 
through high-speed centrifugation, and protein concentrations were determined with a commercially 
available kit (Bio Rad Laboratories, Hercules, CA, USA). Then, 10–40 μg proteins were separated on 10% 
SDS PAGE gels and transferred onto nitrocellulose membranes. These were blocked by incubation for 1 h at 
room temperature with 5% nonfat milk dissolved in TBS Tween 20. The membranes were probed overnight 
with the primary antibodies (Cell Signaling, Danvers, MA, USA, dilution 1/1000) and, after three washes, 
incubated for 1 h with HRP-conjugated secondary antibodies. Bands were detected by chemiluminescence, 
and densitometric analysis was performed with the Multi-Analyst software (version 1.1, Bio-Rad 
Laboratories).  
5.15. Statistical Analysis 
If not differently stated, data are expressed as means ± SEM. (n = 3). Statistical analysis was performed 
with GraphPad Prism 4.0 software. Significance was assessed with Student’s t-test for paired varieties or 
with the one-way ANOVA and the Dunnett test with p ≤ 0.05 as the cut-off. 
Supplementary Materials: The following are available online at www.mdpi.com/link. 
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